FULCRUM THERAPEUTICS INC

NASDAQ: FULC (Fulcrum Therapeutics, Inc.)

Kemas kini terakhir: 2 hari lalu, 5:28PM

12.99

4.09 (45.96%)

Penutupan Terdahulu 8.90
Buka 12.85
Jumlah Dagangan 24,674,474
Purata Dagangan (3B) 670,068
Modal Pasaran 702,998,528
Harga / Jualan (P/S) 2.66
Harga / Buku (P/B) 2.43
Julat 52 Minggu
2.32 (-82%) — 15.74 (21%)
Tarikh Pendapatan 29 Oct 2025
Margin Keuntungan -0.64%
Margin Operasi (TTM) -13.00%
EPS Cair (TTM) -0.010
Pertumbuhan Hasil Suku Tahunan (YOY) -100.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 3.55%
Nisbah Semasa (MRQ) 28.71
Aliran Tunai Operasi (OCF TTM) 7.81 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 4.40 M
Pulangan Atas Aset (ROA TTM) -2.74%
Pulangan Atas Ekuiti (ROE TTM) -0.23%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Fulcrum Therapeutics, Inc. Menaik Menaik

AISkor Stockmoo

-0.8
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -5.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 0.5
Purata -0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
FULC 703 M - - 2.43
IONS 13 B - - 21.49
RNA 11 B - - 5.70
ARWR 10 B - - 17.90
NUVL 8 B - - 9.65
CDTX 7 B - - 16.47

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 1.82%
% Dimiliki oleh Institusi 96.20%
Julat 52 Minggu
2.32 (-82%) — 15.74 (21%)
Julat Harga Sasaran
7.00 (-46%) — 25.00 (92%)
Tinggi 25.00 (HC Wainwright & Co., 92.46%) Beli
Median 18.50 (42.42%)
Rendah 7.00 (B of A Securities, -46.11%) Jual
Purata 17.17 (32.18%)
Jumlah 4 Beli, 1 Pegang, 1 Jual
Harga Purata @ Panggilan 12.78
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
B of A Securities 09 Dec 2025 7.00 (-46.11%) Jual 12.99
Cantor Fitzgerald 08 Dec 2025 24.00 (84.76%) Beli 12.99
HC Wainwright & Co. 08 Dec 2025 25.00 (92.46%) Beli 12.99
24 Nov 2025 18.00 (38.57%) Beli 11.74
Piper Sandler 08 Dec 2025 23.00 (77.06%) Beli 12.99
30 Oct 2025 16.00 (23.17%) Beli 8.60
RBC Capital 08 Dec 2025 10.00 (-23.02%) Pegang 12.99
30 Oct 2025 7.00 (-46.11%) Pegang 8.60
Truist Securities 24 Nov 2025 14.00 (7.78%) Beli 11.74

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
08 Dec 2025 Pengumuman Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
06 Dec 2025 Pengumuman Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
05 Dec 2025 Pengumuman Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2025 Pengumuman Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
07 Nov 2025 Pengumuman Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Nov 2025 Pengumuman Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
29 Oct 2025 Pengumuman Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
22 Oct 2025 Pengumuman Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
14 Oct 2025 Pengumuman Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
10 Oct 2025 Pengumuman Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Sep 2025 Pengumuman Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda